Paul B. Manning
InvestorFounderChairman and CEO at PBM Capital · Board director at Liquidia Corporation · Board director at Taysha Gene Therapies · Board director at Dova Pharmaceuticals
About
Founder of PBM Capital who previously built PBM Products from inception with minimal initial capital into the world's leading private label infant formula supplier serving over 50,000 retail stores, which was sold to Perrigo for over $800 million.
Board director at Liquidia Corporation
Intro paths
In turn, Paul can intro founders to Liquidia Corporation's investors below.
Board director at Taysha Gene Therapies
Intro paths
In turn, Paul can intro founders to Taysha Gene Therapies's investors below.
Taysha Gene Therapies's investors · 2
Co-founders at Taysha Gene Therapies
Board director at Dova Pharmaceuticals
Intro paths
In turn, Paul can intro founders to Dova Pharmaceuticals's investors below.
Dova Pharmaceuticals's investors · 1
Deals · 5
Verrica PharmaceuticalsBoard seat
via PBM Capital · filed Dec 2025 · $50M raise
Taysha Gene TherapiesBoard seat
via PBM Capital · filed Nov 2022 · $30M raise
Xalud Therapeutics, Inc.Board seat
via PBM Capital · filed Jun 2021 · $30M raise
Liquidia CorporationBoard seat
via PBM Capital · filed Apr 2021 · $21.7M raise
ArcherDXBoard seat
via PBM Capital · filed Apr 2020 · $1.6M raise
Attribution from SEC filings, press coverage, and firm rosters.
Colleagues at PBM Capital
Frequently asked questions
- Who is Paul B. Manning?
- Founder of PBM Capital who previously built PBM Products from inception with minimal initial capital into the world's leading private label infant formula supplier serving over 50,000 retail stores, which was sold to Perrigo for over $800 million.
- Where does Paul B. Manning work?
- Paul B. Manning is Chairman and CEO at PBM Capital and Board director at Liquidia Corporation and Board director at Taysha Gene Therapies and Board director at Dova Pharmaceuticals.
- What boards does Paul B. Manning sit on?
- Paul B. Manning holds tracked board seats at ArcherDX, Liquidia Corporation, Taysha Gene Therapies, Verrica Pharmaceuticals, Xalud Therapeutics, Inc..